The Avian Influenza Vaccine Market size is estimated to be valued at USD 140.0 million in 2021 and is poised to grow at a CAGR of 4.2% over 2022-2028. Avian influenza, commonly known as bird flu, is a viral virus that transmits from birds to other animals including people. There are other forms of avian influenza that cause infection, but H5V1 is the most frequent viral strain that affects poultry. Based on strain type, the global avian influenza vaccine market is segmented into type H9, type H7, type H5, and Others. H5 is the most common virus strain segment and holds most of the market share in the global influenza vaccine market. The majority of A(H5) viruses seen in wild birds and poultry are LPAI, however, HPAI A(H5) viruses have also been found. Human infections with A(H5) viruses have been reported sporadically, such as with HPAI A(H5N1) viruses linked to poultry epidemics in various countries across the globe. For instance, in March 2022, highly pathogenic avian influenza A(H5N1) viruses (“H5N1 bird flu viruses”) have been detected in USA wild birds in 14 states. Increasing government initiatives to raise awareness about avian influenza among the farmers, rise in private-sector financing for the development of effective avian influenza vaccines, and increased poultry bird production are expected to contribute to the market growth.
Recent Market Developments:
In October 2019, Ceva and ProBioGen AG signed an exclusive license agreement for the manufacture of vectorized poultry vaccines using ProBioGen’s proprietary AGE1.CR technology.
In October 2018, Boehringer Ingelheim announced the opening of its biological research and development site in France. It invested USD 80.45 million (EUR 70 million) for maintaining its leading position in veterinary vaccines.